1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Breast Tumors: new trials by email Literature Review of Breast Tumors trials Research Report on Breast Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Re-expression of ER in Triple Negative Breast Cancers Decitabine, LBH589, Tamoxifen - Breast Cancer, Breast Tumors | Phase 1 / Phase 2 | Terminated | Emory University | 5 | 2010-07-01 | 2015-01-26 |
| Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer AMG 386 30 mg/kg, Paclitaxel and Trastuzumab, AMG 386 30 mg/kg, Capecitabine and Lapatinib, AMG 386 10 mgkg, Paclitaxel and Trastuzumab - Breast Cancer, Breast Neoplasms | Phase 1 | Completed | Amgen | 65 | 2009-03-09 | 2022-11-08 |
Breast Neoplasms (2) · Neoplasm Metastasis (1) · Neoplasms (1)
Breast Diseases (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Neoplasms (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Capecitabine (1) · Decitabine (1) · Lapatinib (1) · Paclitaxel (1) · Panobinostat (1) · Tamoxifen (1) · Trastuzumab (1) · trebananib (1)
Amgen (1) · Emory University (1)
United States (2) · Belgium (1) · France (1)
Ruth O'Regan, MD (1)